Share on StockTwits

Perrigo Company PLC (NASDAQ:PRGO) will be announcing its Q414 earnings results on Thursday, August 14th. Analysts expect the company to announce earnings of $1.55 per share and revenue of $1.09 billion for the quarter.

Shares of Perrigo Company PLC (NASDAQ:PRGO) traded up 0.32% on Wednesday, hitting $139.44. 1,154,699 shares of the company’s stock traded hands. Perrigo Company PLC has a 1-year low of $115.94 and a 1-year high of $168.39. The stock’s 50-day moving average is $150.1 and its 200-day moving average is $149.0. The company has a market cap of $18.657 billion and a P/E ratio of 76.29.

Several analysts have recently commented on the stock. Analysts at Deutsche Bank initiated coverage on shares of Perrigo Company PLC in a research note on Tuesday, July 22nd. They set a “buy” rating and a $189.00 price target on the stock. On the ratings front, analysts at Morgan Stanley downgraded shares of Perrigo Company PLC from an “overweight” rating to an “equal weight” rating in a research note on Friday, July 11th. Finally, analysts at Argus cut their price target on shares of Perrigo Company PLC from $175.00 to $160.00 in a research note on Thursday, May 15th. They now have a “buy” rating on the stock. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $166.25.

Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (NASDAQ:PRGO) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.

Receive News & Ratings for Perrigo Company PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo Company PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.